Oppenheimer Holdings, Inc. restated their buy rating on shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) in a research report sent to investors on Wednesday morning. The firm currently has a $18.00 price objective on the biotechnology company’s stock.
Other equities research analysts also recently issued research reports about the stock. SunTrust Banks, Inc. reiterated a buy rating and set a $13.00 target price on shares of Mirati Therapeutics in a research note on Thursday, October 12th. HC Wainwright reiterated a buy rating and set a $20.00 target price on shares of Mirati Therapeutics in a research note on Thursday, October 12th. Citigroup Inc. reiterated a buy rating and set a $16.00 target price (up previously from $8.00) on shares of Mirati Therapeutics in a research note on Tuesday, September 19th. Jefferies Group LLC set a $5.00 target price on shares of Mirati Therapeutics and gave the stock a hold rating in a research note on Friday, August 4th. Finally, Zacks Investment Research upgraded shares of Mirati Therapeutics from a sell rating to a hold rating in a research note on Tuesday, November 7th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $13.71.
Shares of Mirati Therapeutics (MRTX) opened at $17.50 on Wednesday. Mirati Therapeutics has a 12 month low of $2.70 and a 12 month high of $19.25.
In related news, SVP Jamie Christensen sold 4,000 shares of the stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $14.00, for a total transaction of $56,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Venbio Select Advisor Llc purchased 650,000 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were purchased at an average cost of $13.00 per share, with a total value of $8,450,000.00. The disclosure for this purchase can be found here. Insiders have sold 23,544 shares of company stock valued at $365,826 over the last three months. 5.10% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of MRTX. Bank of New York Mellon Corp raised its holdings in Mirati Therapeutics by 22.9% during the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 11,753 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Mirati Therapeutics in the first quarter valued at about $677,000. Renaissance Technologies LLC purchased a new position in Mirati Therapeutics in the first quarter valued at about $854,000. KCG Holdings Inc. purchased a new position in Mirati Therapeutics in the first quarter valued at about $106,000. Finally, LMR Partners LLP purchased a new position in Mirati Therapeutics in the second quarter valued at about $236,000. 59.80% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Mirati Therapeutics’ (MRTX) “Buy” Rating Reaffirmed at Oppenheimer Holdings, Inc.” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/11/26/mirati-therapeutics-mrtx-buy-rating-reaffirmed-at-oppenheimer-holdings-inc.html.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
What are top analysts saying about Mirati Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mirati Therapeutics Inc. and related companies.